Use access key #2 to skip to page content.
$31.01 0.14 (0.45%)
10/10/2008 4:00 PM

ICON plc (ADR) (ICLR)

CAPS Rating:
*****

The Company is a contract research organization, providing clinical research and development services on a global basis to the pharmaceutical, biotechnology and medical device industries.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ICLR

Add Stock to Watchlist

What the Community Thinks

Total Members

300 Outperforms
4 Underperforms
 

All-Stars

60 Outperforms
0 Underperforms
 

Wall Street

5 Outperforms
0 Underperforms
 

Members bullish on ICLR are also bullish on:

Members bearish on ICLR are also bearish on:

Ticker Tags

Small Cap (1922), Ireland (10), Research Services (46), Dublin (6)
Suggest a tag

ICON plc (ADR) At A Glance

Current Price: $31.01
Last Trade Time: 10/10/2008 4:00 PM
Open: $28.25
Previous Close: $30.87
Daily Range: $25.05 - $32.30
52-Week Range: $25.78 - $44.78
Volume: 1,089,282
Market Cap: $2.43B
P/E Ratio: 35.24
Compare Our Special Broker Offers!

Stock Trends

ICLR VS S&P 500 (SPY)

ICLR 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for ICLR

More Headlines...

Top Bull Pitch

Recs

1

ICON plc (ADR) (ICLR)

Avatar dollarpimp (36.71) Submitted: 1/18/08 7:38 PM

Discounted earnings valuation assuming 25% earnings growth over 10 years indicates this stock is selling at a substantial discount. Even assuming 20%, it's fairly priced. Just backed off a new high, buying on the dip. Healthcare sector will outperform.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 31 :   1 2 3 4 5 Next »

Recs

0

 (ICLR)

Avatar Actionman2go (< 20) Submitted: 9/09/08 1:18 PM : Outperform Start Price: $38.89 ICLR Score: 9.28

Medical to try and stabilize my bleeding portfolio

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ICLR)

Avatar Tidesurge (31.91) Submitted: 8/19/08 3:17 PM : Outperform Start Price: $41.18 ICLR Score: 5.66

Risk reward ratio is fantastic you get biotech exposure with out the risk

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ICLR)

Avatar stockguy07 (< 20) Submitted: 8/13/08 1:59 PM : Outperform Start Price: $41.65 ICLR Score: 5.84

TM - drug trial outsourcing

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ICLR)

Avatar money4play (73.35) Submitted: 8/11/08 3:32 PM : Outperform Start Price: $43.67 ICLR Score: 2.94

As big pharma trys to reduce costs of geting products to market they will rely more heavily on outsourcing clinical trials.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ICLR)

Avatar Option1307 (50.90) Submitted: 8/05/08 1:43 AM : Outperform Start Price: $41.25 ICLR Score: 4.96

I agree with most that outsouring is going to continue to be an important aspect of the biotech/pharma cost-cutting methods. ICLR is based in Ireland which gives it some insulation against the slowing US economy; however, I doubt the economy will effect this industry either way.

Good balance sheet, increasing sales, EPS, cash flow last 3 yrs. RoE of 16% is mediocre but better than most competitors. P/S of 2.82. IBD rating of 90/96 for EPS/price strength respectively. 17% inside ownership is a nice addition as well.

I know I'm coming in high, but it looks as if its ready to run some more, its still got more Irish luck...

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 31 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 5 of 5  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackUBS 83.70 01/11/08 Outperform NS $33.67-7.90%-37.14%+29.24
TrackWachovia < 20 11/28/07 Outperform NS $28.76+7.80%-38.62%+46.43
TrackJefferies < 20 10/15/07 Outperform NS $27.86+11.31%-43.37%+54.67
TrackEveillard 89.21 09/30/07 Outperform NS $25.51+21.54%-42.00%+63.53 Toggle the visibility of 60-Second Pitch and replies
TrackLehmanBros 73.44 10/30/06 Outperform NS $18.50+67.67%-35.69%+103.35

Results 1 - 5 of 5  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners